Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

By J. Smolen, A. Beaulieu, A. Rubbert-Roth, C. Ramos-Remus, J. Rovensky, E. Alecock, T. Woodworth, R. Alten. The Lancet, 2008

1,401 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Role of proinflammatory cytokines in the pathophysiology of osteoarthritis (2011, background): “The humanized anti-IL-6R antibody tocilizumab improved disease parameters and quality of life, as well as inflammatory markers such as CRP, compared with placebo in phase III trials of patients with RA”
Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550) (2011, background): “To investigate the effects of CP-690,550 on JAK3-independent cytokine receptor signaling, we stimulated CD4 T cells with IL-6, a key inflammatory mediator in CIA and RA (34, 35).”
Toxicities of chimeric antigen receptor T cells: recognition and management. (2016, neutral): “Tocilizumab is an IL-6 receptor antagonist that is used to treat rheumatologic disorders.(63,64) It”
Muscles and their myokines (2011, background): “In addition, changes in lipid profiles were also seen in patients with rheumatoid arthritis receiving IL-6 blocking treatment (Nishimoto et al., 2004; Maini et al., 2006; Smolen et al., 2008).”
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial (2008, methodology): “19 34 Consistent with previous reports, tocilizumab treatment in this study was associated with episodic increases in hepatic aminotransferases.”